Transcription profiling by array of human lung cancer cells after treatment with dasatinib, imatinib, nilotinib or PD0325901

Cell Line: This experiment was designed to measure the transcriptional responses to four kinase inhibitors across a five-logarithm dose range. The A549 human lung cancer cell line was treated with dasatinib, imatinib or nilotinib (4 hours and 20 hours) or PD0325901 (4 hours). Treatments used a 12-point dose range (30 uM with 3-fold dilutions down to 0.17 nM; 0.5% DMSO vehicle for all treatments). Experimental design prevented row or column handling effects being confounded with dose effect.

111

Ji RR, de Silva H, Jin Y, Bruccoleri RE, Cao J, He A, Huang W, Kayne PS, Neuhaus IM, Ott KH, Penhallow B, Cockett MI, Neubauer MG, Siemers NO, Ross-Macdonald P